Skip to content Skip to footer
Menu Close
Close

Clinical Trials for Heart Failure with Preserved or Mildly Reduced Ejection Fraction

Discover how clinical trials are opening new possibilities for better heart failure treatment options for individuals living with HFpEF or HFmrEF.

A New Approach to Heart Failure Care: The Elevate-HF Study

Heart failure with preserved ejection fraction (HFpEF) and heart failure with mildly reduced ejection fraction (HFmrEF) make it harder for the heart to pump blood the way it should. Living with either condition often means managing fatigue, shortness of breath, swelling, and the constant worry of a hospital visit around the corner. For many patients, current treatments only go so far.

The Elevate-HF study is evaluating an investigational medication alongside standard heart failure therapy to learn how effective, safe, and well-tolerated it is in people with HFpEF or HFmrEF, with or without type 2 diabetes. Researchers are studying whether the study drug can lower the risk of cardiovascular death and reduce heart failure hospitalizations or urgent visits. They’re also looking at whether it can help patients feel better and manage their day-to-day lives. This research could help shape future treatment options for people living with this condition.

Age

18 Years and Older

Container

Condition

Heart Failure with Preserved Ejection Fraction (HFpEF) and Heart Failure with Mildly Reduced Ejection Fraction (HFmrEF)

Container

Gender

Both

Container

Current Status

Upcoming

Number of Studies

01

Frequently Asked Questions

HFpEF and HFmrEF are types of heart failure where the heart's pumping chambers do not relax or fill with blood properly, even though the heart's squeezing function is normal or only mildly reduced. Both can cause fatigue, shortness of breath, swelling in the legs or abdomen, and frequent hospital visits.

Clinical trials give patients early access to investigational treatments that may work differently than current standard-of-care options. For this study, participants will continue their prescribed heart failure medication while researchers evaluate whether an additional investigational treatment can further reduce cardiovascular risk and improve daily symptoms.

Eligibility generally includes adults diagnosed with structural heart disease and heart failure symptoms, a measured ejection fraction above 40%, and specific blood test results tied to heart failure severity. A member of the research team will review your full medical history to confirm eligibility.

Get Involved in
Our Clinical Trials Today

Join us in advancing medical research and discover new treatment options that could improve your health and well-being.

Contact Us Today